A new open resource of cancer models has enabled researchers to create the first large-scale map of the genes that cancers rely on to survive, offering new avenues for research into better and less toxic treatments for patients.
Researchers from the Rolf Luft Research Center for Diabetes and Endocrinology at Karolinska Institutet have developed a targeted RNA technology to prepare pancreatic islet cells for transplantation.
Some 33 million Americans have severe food allergies. Now, researchers at Boston Children’s Hospital may have found a promising solution.
Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the “undruggable” PDZ domain of the GIPC1 protein, which helps different types of cancer, including pancreatic cancer, grow and resist treatment. In laboratory studies, the drug slowed tumor growth, improved survival and enhanced the effects of the chemotherapy drug gemcitabine.
Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts cancer cells’ ability to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.
Six years after the height of the COVID-19 pandemic, scientists are still uncovering surprising ways the virus can wreak havoc on the body. A new UCLA study published in Science Advances describes a previously unrecognized way the SARS-CoV-2 nucleocapsid protein—a structural protein less familiar than the spike protein that has dominated public attention and much vaccine research—can push the immune system into dangerous overdrive.
Spinal cord injuries affect an estimated 15 to 20 million people worldwide, often causing lasting impairments in movement, sensation and independence. Such injuries can be especially devastating when they occur at the level of the neck, where damaged spinal circuits disrupt signals that control the diaphragm, the main muscle used for breathing.
BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche’s VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone.
Certification strengthens Koning’s global regulatory foundation as two new Vera Breast CT systems expand patient access in key U.S. markets
Cortechs.ai, a San Diego, CA-based provider of AI-powered quantitative imaging solutions, has announced the expansion of its European CE Marking under the European Union Medical Device Regulation (EU MDR) for its latest imaging products.